AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 141 min read$CLBT

Cellebrite DI Ltd. (NASDAQ:CLBT) Puts CTO Chris Wade in Charge of Cellebrite Labs

Cellebrite DI Ltd. (CLBT) named CTO Chris Wade to lead Cellebrite Labs, focusing on mobile access, extraction, and decoding research. The move follows the Corellium acquisition, aiming to streamline R&D efforts.

Original reporting
tradingview.com
Published Sep 14, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cellebrite DI Ltd. (NASDAQ:CLBT) Puts CTO Chris Wade in Charge of Cellebrite Labs — source image
Source · tradingview.com
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The CTO's new role centralizes R&D, potentially improving speed to market for new forensics tools.

02

Market read

Executive reorganization may affect Cellebrite's product pipeline and investor sentiment.

03

What to watch

Integration challenges post‑Corellium acquisition may offset expected gains.

Relevance 6/10Novelty 5/10Timing: published today

Background

Cellebrite recently acquired Corellium, expanding its mobile security portfolio.

Company-level read

Ticker impact

$CLBTNeutralMedium confidence
Context

CTO Chris Wade appointed to lead Cellebrite Labs within the Innovation Hub.

Expected impact

Potential modest upside if labs deliver faster releases.

Evidence & confidence

Executive reorg is a primary disclosure but lacks immediate financial metrics.

Market effects

Sector

May signal increased focus on mobile forensics R&D across the sector.

Regional

Limited to U.S. and global customers of Cellebrite.

Global

Low, as impact is company‑specific.

Counterpoint

What could challenge this read

Reorg could distract management and delay product pipelines.

Key entities

  • Company
    Cellebrite DI Ltd.

    Provider of digital intelligence solutions.

  • Executive
    Chris Wade

    Chief Technology Officer appointed to lead Cellebrite Labs.

Read at source← All news

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min